Allegheny Health Network | Association Partnerships

David L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.

David L. Bartlett, MD, discusses the benefits of genomic testing for patients with cancer and how the approach to genomic testing has changed over the years.

In an interview with Targeted Oncology, Nasir Chaudry, MD, discussed the evolving landscape of prostate cancer treatment, driven by new research.

In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.

Researchers from Allegheny Health Network, Baylor Scott & White Health, and Johns Hopkins Medicine have found that two newly approved immunotherapies can help to improve two-year survival rates for patients with gastroesophageal cancers.

Lifileucel's FDA approval marks a breakthrough in melanoma treatment, offering hope with promising antitumor activity. While its potential extends to various solid tumors, challenges persist.

Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.

In an interview with Targeted Oncology, Howard D. Edington, MD, discussed Allegheny Health Network’s recently unveiled Melanoma and Skin Cancer Center and its new technology.

Ariel Lopez-Chavez, MD, provided insights into the current landscape of small cell lung cancer treatment, highlighting approved options and ongoing research.

Peterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.

John Nakayama, MD, discusses the significance of the NRG GY018 study in endometrial cancer.

Oncologists at Allegheny Health Network share updates on their latest approaches for optimizing surgical and systemic treatment in patients with pancreatic cancer.

Nasir Chaudry, MD, discusses treatment decisions for patients with prostate cancer and the importance of individualized treatment based on the specific case and patient preferences.

In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the dynamic landscape of ovarian cancer treatment.

Allegheny Health Network Cancer Institute’s (AHNCI) Radiation Oncology program recently attained accreditation from the American Society for Radiation Oncology APEx - Accreditation Program for Excellence® for all 13 of its radiation oncology facilities.

The Allegheny Health Network Cancer Institute (AHNCI) announced today that it has established one of the region’s first clinics dedicated to precision cancer medicine and has appointed nationally recognized medical oncologist Ariel Lopez-Chavez, MD, MS, to serve as director of the new clinic.

Allegheny Health Network announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.

In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.

Nasir Chaudry, MD, discusses the significant advancements in the prostate cancer space in recent years.

Ariel Lopez-Chavez, MD, discusses available frontline options for patients with small cell lung cancer, then moves into second-line treatments.

In an interview for World Neuroendocrine Cancer Awareness Day, Casey J. Allen, MD, discussed the advances in treatment for these patients with gastrointestinal neuroendocrine tumors.

$16 Million Facility Includes Region’s First 3D Whole Body Imaging System to Detect Skin Abnormalities, Such as Potential Melanomas

Lisa B. Ercolano, MD, discusses some of the advances that have been seen in the treatment of sarcomas.

Salman Fazal, MD, discusses acute and chronic graft-versus-host-disease and younger match unrelated donor transplant for patients with cancer.

Cyrus M. Khan, MD, discusses the eligibility criteria of a phase 1/2 study evaluating glofitamab for the treatment of patients with large B-cell lymphoma, and provides data from the expansion cohorts of the trial.

Eirwen M. Miller, MD, discusses novel biomarkers that she believes will be important for endometrial cancer in the future.

Cyrus M. Khan, MD, discusses pirtobrutinib for the treatment of mantle cell lymphoma and findings from the phase 1/2 BRUIN study.

Benny Weskler, MBA, MD, FACS, FACCP, discusses the introduction of immune checkpoint inhibitors in the neoadjuvant setting for patients with non–small cell lung cancer.

In an interview, Nathan Bahary, MD, PhD, explains what factors have contributed to the rise in oncology drug shortages, and emphasizes the importance of proactive measures moving forward, while also suggesting the importance of policy changes and increased communication.

Cyrus M. Khan, MD, discusses the phase 1/2 trial of glofitamab for use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.